Reliance Global Group (EZRA) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
31 Jul, 2026Executive summary
Organization simplified, balance sheet strengthened, and operations streamlined to position for long-term growth, with a strategic focus on insurance and technology-driven initiatives.
Leadership team enhanced with new COO, CTO, and EVP appointments to drive operational and technological advancement.
Accelerated deployment and launch of proprietary AI platform and secure browser automation agent to automate insurance workflows and enhance efficiency.
Continued organic growth in retained insurance operations after divesting non-core businesses.
Completed a 1-for-40 reverse stock split in May 2026 to regain Nasdaq compliance.
Financial highlights
Q2 2026 commission income was $2.1M, down from $3.1M year-over-year, reflecting divestitures and portfolio realignment.
Operating expenses for Q2 2026 were $3.9M, down 28% year-over-year due to cost management and efficiencies.
Net loss improved by 26% year-over-year to $2.0M from $2.7M, driven by efficiencies and lower non-cash compensation.
Adjusted EBITDA loss was $1.1M, compared to a $0.4M loss in the prior year quarter.
As of June 30, 2026: cash and restricted cash totaled $1.8M, working capital was $1.2M, and stockholders’ equity was $6.6M.
Outlook and guidance
Continued enhancement and deployment of proprietary AI platform, expected to generate revenue within six to nine months and further improve productivity.
Management believes current liquidity and access to capital are sufficient for at least the next 12 months.
Ongoing evaluation of commercialization opportunities for AI technology and disciplined approach to capital allocation.
Strategic focus remains on insurance operations and expanding AI capabilities.
Latest events from Reliance Global Group
- Net loss improved, cash and equity grew, and insurance saw 11% organic growth.EZRA
Q1 20268 Jul 2026 - All proposals passed, with leadership focused on growth and stockholder value.EZRA
AGM 20266 May 2026 - Strategic tech expansion, divestitures, and improved financials position for future growth.EZRA
Q4 20256 May 2026 - Strategic investment in Innervate Radiopharmaceuticals advances late-stage healthcare platform exposure.EZRA
Proxy filing4 May 2026 - Annual meeting seeks approval for director elections, equity plan expansion, and major share issuance.EZRA
Proxy filing23 Mar 2026 - Shareholders will vote on director elections, equity plan expansion, and a $50M share issuance.EZRA
Proxy Filing12 Mar 2026 - Q2 net loss improved 62%, Spetner deal to double revenue and boost profitability.EZRA
Q2 20242 Feb 2026 - Raising $5.3M for growth, tech, and digital assets amid dilution and Nasdaq compliance risks.EZRA
Registration Filing23 Jan 2026 - Q3 2024 delivered revenue growth, cost cuts, positive Adjusted EBITDA, and major M&A and tech moves.EZRA
Q3 202415 Jan 2026